The Biologics Manufacturing core for this SPORE application is dedicated to the production of clinical trial materials according to programmatic requirements outlines in the individual projects and all applicable state, local and Federal regulations for investigational products. The core is divided into three production groups; cell products, monoclonal antibodies and viral vectors. Each group is led by a Director with extensive experience in the production of clinical trials materials and Good Manufacturing Practices (GMP). Each group is supported by a Quality Systems Team (Quality Assurance and Quality Control) that ensures that testing and documentation of investigational product manufacturing is performed according to the applicable regulations. Manufacturing will occur at two sites. The Center for Biomedicine and Genetics (CBG) and the Laboratory for Cellular Medicine (LCM) manufacturing facility in the new Arnold and Mabel Beckman Center for Cancer Immunotherapeutics and Tumor Immunology completed in 2009. Monoclonal antibodies and constructs for Projects 1, 3 and 4 and Viral vectors for Project 1 will be manufactured in the CBG while cell products for Project 1 will be manufactured in the LCM. Over the past five years monoclonal antibody products have been produced for the previous SPORE Projects 1,2,4 and 5, some of which have been used in clinical trials. Extensive development of manufacturing, conjugating and vialing procedures for MAb products has taken place. A new method for the conjugation of MAbs at clinical scale quantities has been developed and recently published. The Laboratory for Cellular Medicine (LCM) has manufactured products for the previous iteration of SPORE Project 2 (Adoptive Immunotherapy for Follicular Lymphoma), is currently manufacturing products for Mantle Cell/DLBC Lymphoma (Project 1). Extensive process development has taken place in the areas of closed system cell processing, cell selection, lentiviral-based genetic modification and expansion in preparation for manufacturing investigational cell products for Lymphoma and other hematological malignancies. Plasmid DNA and Viral vectors have been manufactured for Follicular Lymphoma and Mantle Cell/DLBC Lymphoma protocols and are currently being developed for treating NHL patients for SPORE Project 1.

Public Health Relevance

The Biologics Manufacturing Core is dedicated to the production of clinical materials described in this application. Manufacturing is performed in two fully GMP compliant manufacturing facilities on the campus of City of Hope. Each product type (monoclonal antibodies, cell products and viral vectors) is manufactured by a team of trained professionals who ensure the product meets the purity, potency, identity and safety requirements established by Federal regulations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Rohr, J; Guo, S; Huo, J et al. (2016) Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. Leukemia 30:1062-70
Wang, Sophia S; Deapen, Dennis; Voutsinas, Jenna et al. (2016) Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort. Br J Haematol 174:480-3
Zhang, Chunyan; Xin, Hong; Zhang, Wang et al. (2016) CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44:913-23
Beharry, Andrew A; Lacoste, Sandrine; O'Connor, Timothy R et al. (2016) Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker. J Am Chem Soc 138:3647-50
You, Changjun; Wang, Pengcheng; Nay, Stephanie L et al. (2016) Roles of Aag, Alkbh2, and Alkbh3 in the Repair of Carboxymethylated and Ethylated Thymidine Lesions. ACS Chem Biol 11:1332-8
Wang, Xiuli; Popplewell, Leslie L; Wagner, Jamie R et al. (2016) Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127:2980-90
Küçük, Can; Hu, Xiaozhou; Gong, Qiang et al. (2016) Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma. Am J Pathol 186:1435-41
Zhou, Jiehua; Rossi, John J; Shum, Ka To (2015) Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge. Methods Mol Biol 1297:169-85
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Zhang, Wang; Zhang, Chunyan; Li, Wenzhao et al. (2015) CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. Eur J Immunol 45:71-81

Showing the most recent 10 out of 81 publications